Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

33.3%

2 terminated/withdrawn out of 6 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

67%

4 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 4

4(66.7%)

N/A

2(33.3%)

6Total

Phase 4(4)

N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT06952998Phase 4Recruiting

Efficacy of Plasma Rich in Growth Factors (PRGF) in the Treatment of Foot Ulcers in Diabetic Patients With Peripheral Arterial Disease

Role: lead

NCT06715085Phase 4Recruiting

PRGF-ENDORET® Infiltrations in the Treatment of Low Back Pain.

Role: lead

NCT02707120Phase 4Withdrawn

Efficacy and Safety of Plasma Rich in Growth Factors (PRGF-Endoret) Eye-drops in the Treatment of Neurotrophic Keratitis

Role: lead

NCT01885676Not ApplicableWithdrawn

Plasma Rich in Growth Factors (PRGF-Endoret)in the Treatment of Androgenetic Alopecia

Role: lead

NCT01771302Not ApplicableCompleted

Efficiency of PRGF-Endoret in Combination With a Bone Graft in Lateral Sinus Floor Elevation

Role: collaborator

NCT00782197Phase 4Completed

Autologous Plasma Rich in Growth Factors (PRGF) Treating the Symptomatic Knee OA

Role: lead

All 6 trials loaded